UTRN and Duchenne muscular dystrophy: For example, “Ezutromid,” an orally administered small molecule that modulates utrophin production, was clinically tested as a novel DMD treatment despite not meeting the primary endpoint in phase 2 clinical trials (NCT02858362, PhaseOut DMD) (52, 53).